Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05230173 · ClinicalTrials.gov registry record · NA

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

A NA study of Ulcerative Colitis and Crohn Disease, sponsored by University of California, San Diego.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
20
Study locations

NCT05230173 is a NA study of Ulcerative Colitis and Crohn Disease that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 250 participants, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05230173, a NA study of Ulcerative Colitis and Crohn Disease, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.

Conditions Studied

Ulcerative Colitis Crohn Disease

Interventions

  • OTHER Pragmatic

Study Locations (20)

California

  • Hoag Hospital - Irvine
  • UC San Diego Health - La Jolla
  • Cedars-Sinai - Los Angeles
  • Sutter Health - Palo Alto

New York

  • Saratoga Schenectady Gastroenterology Associates - Burnt Hills
  • NYU Langone Health - New York
  • Cornell University - New York
  • University of Rochester - Rochester

Texas

  • University of Texas Southwestern - Dallas
  • Baylor College of Medicine - Houston

Colorado

  • University of Colorado - Aurora

Connecticut

  • Yale University - New Haven

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Illinois

  • University of Chicago Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-10-05
Est. Completion 2028-06-01
Phase NA

Sponsor

University of California, San Diego

775 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05230173

The ClinicalTrials.gov registry entry for NCT05230173 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (88% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Pragmatic is the first listed.

NCT05230173 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT05230173 about?

NCT05230173 is a clinical study titled "Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission". The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulc...

What is the current status of trial NCT05230173?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2022-10-05. Estimated completion is 2028-06-01.

What conditions does trial NCT05230173 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease.

What interventions are being tested in trial NCT05230173?

The interventions under investigation include: Pragmatic (OTHER).

Who is sponsoring clinical trial NCT05230173?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05230173 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

Crohn Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.